Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Extension of Previously Announced Tender Offer for Shares of Allos Therapeutics

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum) and Allos Therapeutics, Inc. (NasdaqGS: ALTH) (Allos) today announced that, on May 9, 2012, each had received from the Federal Trade Commission (FTC) a Request for Additional Information and Documentary Material (Second Request) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Allos by Spectrum. Both parties are continuing to cooperate with the FTC.

Back to news